Oncopeptides

1.484

SEK

-1.59 %

ONCO

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

2 following

-1.59%

-3.39%

-30.16%

-48.65%

-72.81%

-73.63%

-75.67%

-98.42%

-95.16%

Oncopeptides is a biotech company that develops drugs for difficult-to-treat hematological diseases. The company uses its PDC platform to develop peptide-linked drugs that selectively deliver cytotoxic drugs into cancer cells. The company has drugs in commercialization and several drug candidates under development. Oncopeptide's head office is located in Stockholm.

Market cap

319.34M SEK

Turnover

905.05K SEK

Revenue

35.22M

EBIT %

-719.62 %

P/E

-

Dividend yield-%

-

Financial calendar

27.2

2025

Annual report '24

8.5

2025

Interim report Q1'25

22.5

2025

General meeting '24

ShowingAll content types

Regulatory press release11/27/2024, 12:49 PM

Oncopeptides obtains reimbursement for Pepaxti in Italy

Regulatory press release11/22/2024, 7:30 AM

Oncopeptides announces the Nomination Committee

Press release11/20/2024, 7:30 AM

Oncopeptides invited to present data on PDC platform efficacy in Acute Myeloid Leukemia at the American Society of Hematology meeting

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Press release11/8/2024, 12:33 PM

Redeye: Oncopeptides Q3 2024 - Sluggish Growth

Oncopeptides, Audiocast with teleconference, Q3'24

Webcast11/7/2024, 9:00 AM

Oncopeptides, Audiocast with teleconference, Q3'24

Regulatory press release11/7/2024, 7:00 AM

Oncopeptides publishes Q3 report 2024

Press release11/4/2024, 10:00 AM

Oncopeptides AB: Oncopeptides will present at the BioStock Life Science Summit, November 20

Press release10/31/2024, 7:30 AM

Invitation to presentation of the Q3 report 2024

Press release9/12/2024, 11:00 AM

Oncopeptides signs license agreement with SCBIO for Pepaxti in South Korea

Press release8/15/2024, 6:13 AM

Redeye: Oncopeptides Q2 2024 - Strong Q/Q Sales Growth

Oncopeptides, Audiocast with teleconference, Q2'24

Webcast8/14/2024, 7:00 AM

Oncopeptides, Audiocast with teleconference, Q2'24

Regulatory press release8/14/2024, 6:00 AM

Oncopeptides publishes Q2 report 2024

Press release8/8/2024, 7:00 AM

Invitation to presentation of the Q2 report 2024

Press release7/22/2024, 6:30 AM

First patient enters Oncopeptides study aiming to gain real-world insights from Pepaxti in Germany

Regulatory press release6/28/2024, 6:00 AM

Number of shares and votes in Oncopeptides

Press release6/27/2024, 6:00 AM

Oncopeptides selects first candidate drug from its SPiKE platform

Regulatory press release5/31/2024, 11:20 AM

Bulletin from the Annual General Meeting in Oncopeptides AB (publ)

Regulatory press release5/31/2024, 6:30 AM

Number of shares and votes in Oncopeptides

Oncopeptides, Audiocast with teleconference, Q1'24

Webcast5/30/2024, 7:00 AM

Oncopeptides, Audiocast with teleconference, Q1'24

Regulatory press release5/30/2024, 6:45 AM

Oncopeptides issues warrants to fulfil its obligations under loan agreement with EIB

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.